Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.
Also called NCT01546532
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 118 participants
- Sponsor
- Registry
-
NCT01546532 -
2011-001588-37
-
- Other papers using this trial's data
- Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Germany, Netherlands, Poland
- Registry status
- Completed
Technical summary
Registry record NCT01546532. Randomized; quadruple masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2012-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
- Condition
- Chronic Heart Failure (CHF)
- Intervention (Drug)
- RLX030
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01546532- Content hash
e1c18fe7f29934b44741ec5a39f5d267a4e15f2f5e14cbb3de902af2486f5622